<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition</h1>
      <div class="meta">2025-09-09 12:10:32+00:00 UTC</div>
      <ul>
        <li>Novartis will pay $48.00 per share in cash at closing, a 59% premium to Tourmaline’s September 8 closing price and 127% above its 60-day volume-weighted average.</li>
        <li>The deal is expected to close in the fourth quarter of 2025.</li>
        <li>If the milestone is achieved, total consideration, including the CVR, would be approximately $1.7 billion.</li>
        <li>In April, Novartis acquired Regulus Therapeutics for an initial payment of $7.00 per share in cash or $0.8 billion.</li>
        <li>Other Deals In 2025 To Bolster Heart and Kidney Drug Portfolio Earlier in 2025, Novartis agreed to acquire Anthos Therapeutics Inc.</li>
        <li>for an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.</li>
        <li>(NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/news/novartis-expand-heart-drug-portfolio-121032541.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=Novartis+To+Expand+Heart+Drug+Portfolio+With+%241.4+Billion+Tourmaline+Bio+Acquisition%0A%E2%80%A2+Novartis+will+pay+%2448.00+per+share+in+cash+at+closing%2C+a+59%25+premium+to+Tourmaline%E2%80%99s+September+8+closing+price+and+127%25+above+its+60-day+volume-weighted+average.%0A%E2%80%A2+The%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fnovartis-expand-heart-drug-portfolio-121032541.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
